A Rare Setup in the Market's 'Exception' Stocks

A rare opportunity is unfolding in this boom-and-bust sector. In fact, it only comes around once or twice in a lifetime... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [DailyWealth] Editor's note: Biotech stocks took a hit last year. Some are still being unfairly punished today. And according to Joel Litman – founder of our corporate affiliate Altimetry – that's setting up an atypical situation... and a rare buying opportunity. In this article, adapted from yesterday's issue of the free Altimetry Daily Authority e-letter, Joel details how to take advantage of the market's "exception" in this boom-and-bust sector... --------------------------------------------------------------- A Rare Setup in the Market's 'Exception' Stocks By Joel Litman, chief investment strategist, Altimetry --------------------------------------------------------------- Most companies wait until they're making money before tapping the public market for cash... Public-market investors just don't have the patience for startups that are a ways off from being profitable. And they're certainly not OK with risking dozens of failures for every one success story. But there's one corner of the market that's the exception to this investing rule... I'm talking about biotech. Biotech companies take "capital intensive" to an extreme. They funnel cash into labs to develop potential drug therapies. Then they pay tens – or sometimes hundreds – of millions of dollars to take those compounds through trials. Even after all that, 75% of drugs that get through Phase I clinical trials still fail. And if a treatment gets approved by the U.S. Food and Drug Administration and other regulators, the company has to make the drug at scale. That takes even more spending on a ton of equipment. Because of those capital needs, biotech companies have to tap the deeper public equity markets sooner than most startups. These companies can soar when things go right... So public investors are willing to take that bet. And as I'll explain today, we're now seeing a biotech opportunity so rare, it only comes around once or twice in a lifetime. --------------------------------------------------------------- Recommended Links: [Bitcoin Is Set to 'Reboot' on April 19]( Every single time bitcoin has "rebooted" in the past, the best altcoins went up by thousands of percent. We've seen gains like 1,300% in one month on Feathercoin... 19,858% in 17 months on Dash... and 53,414% in 13 months on Litecoin. [Here's our No. 1 crypto to buy BEFORE April 19](. --------------------------------------------------------------- [Here's What You Missed Last Week]( A rare market anomaly just caused one company to jump 275% in only two weeks... and another to skyrocket 170% IN A SINGLE TRADING DAY. It has nothing to do with the "Magnificent Seven" or the presidential election... and it doesn't involve trading options or bitcoin. Yet two renowned experts believe it may be the absolute biggest "no brainer" moneymaking opportunity of 2024. [Get the full details here](. --------------------------------------------------------------- Even under "normal" circumstances, the right biotech investment can lead to gains that are practically unheard of... Consider Biogen (BIIB), a pioneer in treatments for diseases like Alzheimer's and spinal muscular atrophy. Shares are up more than 29,000% over the past 30 years. Gilead Sciences (GILD), which marketed one of the first hepatitis C cures, is up around 21,500% since 1994. And Amgen (AMGN), whose top product treats postmenopausal osteoporosis, is up more than 210,000% since the 1980s. This kind of upside potential means lofty valuations for most biotech startups. Investors want in – even when those companies might be a decade away from actual revenue if everything goes right. That's what makes today's opportunity so special... There are more than 500 biotech microcaps – meaning those with market caps below $2 billion. And right now, more than a fifth of them are trading for less than enterprise value ("EV"), or the value of the cash on their balance sheets. These are what we refer to as "negative EV" companies. And even for biotechs this far away from making a profit, it's rare to see so many trading for negative EV. For many of these companies, the setup is probably justified. More biotech startups should trade at those valuations all the time. With interest rates high and the capital markets closed to unprofitable businesses, they'll struggle to access capital in the coming months. However, not all negative-EV biotechs deserve that designation... Some of these stocks have been unfairly dragged down. Investors aren't taking the time to figure out which companies have real promise to deliver a drug... or which might not even need financing as long as rates stay high. My team and I have spent weeks tracking this setup... We pored over the 115 biotech stocks that appeared to be negative-EV at first glance. And we found that only 51 actually qualified as negative-EV. That's when the real work started. We distilled those 51 potential biotech blockbusters down to a list of five "buys" today... plus another eight that could be promising in the near future. And in the process, we also "sounded the alarm" on five dangerous biotechs that could wreck an unsuspecting investor's portfolio. I don't expect this opportunity to last much longer. Some of the stocks I tracked during my research soared hundreds of percent in weeks... days... and even a single trading day. So if you want to learn more about what we're seeing, I urge you to watch the free replay of my presentation, in full, [right here](. Setups like these don't come around often. Be sure to take advantage of them when they do. Regards, Joel Litman --------------------------------------------------------------- Editor's note: Stansberry Research founder Porter Stansberry recently sat down with Joel to break down the historic anomaly that's disrupting the biotech sector. This kind of event only happens once or twice in a lifetime... and could deliver staggering gains to those who know how to position themselves correctly. But this window of opportunity won't last long... [Click here to learn the details](. Further Reading Biotech companies used to be able to raise cash instantly. That's no longer the case today. Even still, committed firms aren't shying away from investing in this industry – and now, signs are pointing to a rebound in this space... [Read more here](. Japan's economy is short on young workers. But with the help of robots and AI "avatars," the country is combatting these setbacks. We'll likely see more automation as workforces age around the world. And one company stands to benefit... [Learn more here](. --------------------------------------------------------------- [Tell us what you think of this content]( [We value our subscribers' feedback. To help us improve your experience, we'd like to ask you a couple brief questions.]( [Click here to rate this e-mail]( You have received this e-mail as part of your subscription to DailyWealth. If you no longer want to receive e-mails from DailyWealth [click here](. Published by Stansberry Research. You're receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2024 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.